Improvement of Persistent Detrusor Overactivity through Treatment with a Phytotherapeutic Agent (WSY-1075) after Relief of Bladder Outlet Obstruction.
- Author:
Su Jin KIM
1
;
Seung Hwan JEON
;
Eun Bi KWON
;
Hyun Cheol JEONG
;
Sae Woong CHOI
;
Woong Jin BAE
;
Hyuk Jin CHO
;
U Syn HA
;
Sung Hoo HONG
;
Ji Youl LEE
;
Sung Yeoun HWANG
;
Sae Woong KIM
Author Information
- Publication Type:Original Article
- Keywords: Lower urinary tract symptoms; Phytotherapy; Prostatic hyperplasia; Urinary bladder, overactive
- MeSH: Animals; Cytokines; Humans; Interleukin-8; Lower Urinary Tract Symptoms; Models, Animal; Necrosis; Oxidative Stress; Phytotherapy; Prostatic Hyperplasia; Rats; Receptors, Muscarinic; Superoxide Dismutase; Urinary Bladder Neck Obstruction*; Urinary Bladder*; Urinary Bladder, Overactive
- From:The World Journal of Men's Health 2018;36(2):153-160
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Many patients with benign prostatic hyperplasia need treatment for remaining storage symptoms after surgery. Therefore, we evaluated the effect of the phytotherapeutic agent WSY-1075 on persistent detrusor overactivity (DO) after the relief of bladder outlet obstruction (BOO). MATERIALS AND METHODS: Rats were assigned to 3 groups: control (n=6), persistent DO (n=6), and persistent DO treated with the phytotherapeutic agent WSY-1075 (n=6). Persistent DO after relief of partial BOO was generated in the rat model, and 6 of the rats with this condition were orally administered WSY-1075. After 4 weeks of administration, cystometry was performed. Additionally, 8-hydroxy-2-deoxyguanosine and superoxide dismutase were measured to evaluate oxidative stress in the bladder. Pro-inflammatory cytokines, such as interleukin-8 and tumor necrosis factor-α, were analyzed, as were the M2 and M3 muscarinic receptors of the bladder. RESULTS: Significantly increased contraction pressure and a decreased contraction interval were observed in the persistent DO group after relief of BOO. Moreover, oxidative stress, pro-inflammatory cytokines, and M3 muscarinic receptors were significantly increased. After treatment with WSY-1075, significantly reduced DO was observed by cystometry in comparison with the persistent DO group. Additionally, significantly decreased levels of oxidative stress, pro-inflammatory cytokines, and M3 muscarinic receptors in the bladder were observed after treatment with WSY-1075. CONCLUSIONS: Treatment with WSY-1075 improved persistent DO after the relief of BOO mediated by antioxidative and anti-inflammatory effects. Further studies are necessary to identify the exact mechanism of the treatment effect of WSY-1075.
